Inpatient Blood Glucose Control in Taichung Veterans General Hospital

HYPERGLYCEMIA Clinical Trial

Official title:

The Effects of Glucose Control and Monitor on Inflammation in the Hospitalized Patients With Hyperglycemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02885909
• Other study ID #: CF16199B
• Status: Recruiting
• Phase: Phase 4
• Start date: September 2016
• Est. completion date: December 2025

Study information

• Verified date: December 2019
• Source: Taichung Veterans General Hospital
• Contact: I-Te Lee, MD, PhD
• Phone: +886-4-23592525
• Email: itlee[@]vghtc.gov.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be conducted in the ward of Taichung Veterans General Hospital. The patient with hyperglycemia in hospitalization will be enrolled by glucose management team.

Description:

This study will be conducted in the ward of Taichung Veterans General Hospital. The type 2 diabetic patient with hyperglycemia in hospitalization are candidates. The glucose will be controlled using the insulin protocal based on the glucose monitor systems. We will assess the effects of insulin protocal and glucose monitor system on the inpatient with hyperglycemia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: December 2025
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Type 2 diabetic inpatient

• Fasting glucose >140 mg/dl or random glucose >180 mg/dl

Exclusion Criteria:

• incooperative for glucose monitor

• refusal of insulin

• pregnancy

Related Conditions & MeSH terms

• HYPERGLYCEMIA

Intervention

Device:
• CONTINUE GLUCOSE MONITOR
Continue glucose monitor

Procedure:
• Insulin protocal
Using insulin protocal based on glucose monitor

Locations

Country	Name	City	State
Taiwan	Taichung Veterans General Hospital	Taichung

Sponsors (1)

Lead Sponsor	Collaborator
Taichung Veterans General Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glucose target	The ratio of glucose less than 180 mg/dl	6 days
Secondary	Fasting glucose target	the ratio of fasting glucose less than 140 mg/dl	6 days
Secondary	Hypoglycemia	symptoms or less than 70	times
Secondary	Vascular Cell Adhesion Molecule 1 (VCAM-1)	Inflammation	6 days
Secondary	Brain-Derived Neurotrophic Factor (BDNF)	Psychological assessment	6 days
Secondary	Orexin-A	Psychological assessment	6 days